4 results about "Anti malarial" patented technology

According to the purposes of the present disclosure, as embodied and broadly described herein, the present disclosure relates, in one aspect, to scaffold molecules that exhibit potent anti-malarial activity against a variety of Plasmodium strains at different stages of a parasite, such as the red and infrared stages, and pharmaceutical compositions comprising the scaffold molecules. In one aspect, these compounds are tetrahydroacridones having Structure I described herein. In another aspect, the compounds described herein may be used to treat or prevent malaria in a subject.

The present invention provides an antimalarial composition comprising arjunetin and artemisinin. The composition exhibits synergistic antimalarial effect against malaria causing Plasmodium species including Plamsodium falciparum, P berghe species. The composition comprising Arjunetin and Artemisinin demonstrated potent antimalarial activity in vivo and in vitro with better survival and low parasite burden in the blood.

Systems, compositions, devices, methods, etc., provide improved anti-malaria immunological responses comprising making, providing and administering vaccines comprising specific RNA molecules such as self-replicating replicon RNA (repRNA) encoding proteins from Plasmodium such as the P. yoelii (Py) CS protein (CSP), including in some embodiments substantially target proteins encoding target antigens, for example a whole or substantially whole CSP in the repRNA. The prime-and-trap intervals for the administration of the vaccine can comprise administration of only a single dose of a repRNA-Non-encapsulating oil-in-water emulsion nanocarriers (e.g., LION™) component followed by administration of as few as 3 or 2 doses, or even just a single dose, of the WO component (e.g., RAS or genetically attenuated WO) at 0 day (same day), or 1, 2, 3, 4, 5, 10, 14, 15 days or 28 days later.

The application discloses an AKK and / or outer membrane vesicle thereof induced macrophage polarization method and application thereof in preparation of a medicine for promoting phagocytosis of infected red blood cells by macrophages, and belongs to the technical field of biological medicines. It is found by the application that macrophages are subjected to M1 polarization phenomenon after being induced by AKK bacteria or OMVs thereof. The macrophages subjected to M1 polarization produce proinflammatory factors, and phagocytose more red blood cells infected by Plasmodium. In the absence of existing anti-malaria medicines, compared with macrophages not subjected to M1 polarization, the macrophages subjected to M1 polarization only by AKK bacteria or AKK-OMVs can phagocytose more red blood cells infected by Plasmodium, effectively avoiding the resistance of Plasmodium to anti-malaria medicines caused by long-term use of the anti-malaria medicines, and providing a new scheme for clinical malaria treatment.